已收盘 12-12 16:00:00 美东时间
+1.390
+1.68%
今日重点评级关注:Canaccord Genuity:维持Fractyl Health"买入"评级,目标价从6美元升至8美元;HC Wainwright & Co.:维持MediWound"买入"评级,目标价从31美元升至36美元
11-24 11:23
BWS Financial analyst Hamed Khorsand downgrades Interparfums (NASDAQ:IPAR) from Buy to Neutral and announces $85 price target.
11-22 02:53
今日重点评级关注:富国银行:维持Annexon"超配"评级,目标价从14美元升至27美元;瑞穗:上调Relmada Therapeutics评级至"跑赢大市",目标价从1美元升至10美元
11-20 10:28
Canaccord Genuity analyst Susan Anderson maintains Interparfums (NASDAQ:IPAR) with a Buy and maintains $123 price target.
11-19 22:23
Inter Parfums ( ($IPAR) ) has issued an update. Interparfums, Inc. announced it...
11-19 06:07
Interparfums shares are trading lower. The company issued FY26 guidance.
11-19 05:33
Interparfums (IPAR) on Tuesday issued initial guidance for 2026, forecasting net sales of $1.48 billion, up 1% from its 2025 outlook, and diluted earnings of $4.85 per share, a 5% decline. The company...
11-19 05:21
Jean Madar, Chairman & Chief Executive Officer of Interparfums noted, "In 2026, we will focus on consolidation and lay the foundations for long term, profitable growth. While current market dynamics largely influence
11-19 05:20
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 17:17
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
11-10 10:22